ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Diagnostic Accuracy of Anti-factor Xa Activity, PT, and APTT for Clinically Relevant Rivaroxaban Levels in Older AF Patients.
Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundRapid assessment of rivaroxaban exposure is clinically critical for older patients with atrial fibrillation in scenarios such as acute bleeding, urgent invasive procedures, or thrombolysis decision-making. This study evaluated rivaroxaban-calibrated anti-factor Xa activity (anti-FXa activity), prothrombin time (PT), and activated partial thromboplastin time (APTT) for identifying clinically relevant rivaroxaban concentrations in older atrial fibrillation patients.MethodsIn this prospective multicenter diagnostic accuracy study, older patients with atrial fibrillation receiving rivaroxaban were enrolled. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used as the reference standard, with ≥50 ng/mL defined as the primary diagnostic threshold. Anti-FXa activity, PT, and APTT were evaluated as index tests. Diagnostic performance was assessed using receiver-operating-characteristic analysis, Youden-derived cut-offs, and patient-level clustered bootstrap resampling.ResultsA total of 183 patients were included, contributing 350 LC-MS/MS samples. Anti-FXa activity showed the highest discrimination for identifying LC-MS/MS-measured rivaroxaban concentrations ≥50 ng/mL, with an area under the receiver-operating characteristic curve (AUC) of 0.980 (95% confidence interval [CI], 0.960-0.993), followed by PT (0.904; 95% CI, 0.869-0.938) and APTT (0.825; 95% CI, 0.779-0.869). At Youden-derived cut-offs, anti-FXa activity had sensitivity of 94.0% and specificity of 96.1%, compared with 84.8% and 85.4% for PT, and 74.4% and 81.0% for APTT. Spearman correlations with LC-MS/MS were strongest for anti-FXa activity, followed by PT and APTT.ConclusionIn this cohort of older patients with AF, anti-factor Xa activity showed the highest diagnostic accuracy for identifying rivaroxaban concentrations ≥50 ng/mL, whereas PT provided moderate discrimination and APTT was less informative.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.